retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished VisualAbstract: Retatrutide reduces body weight

Here are some key benefits: 1

S.MohamedR

Glutathione skin whitening injections may achieve a lighter skin tone by reaching the desired concentration levels of these pigments

This article contains the most recent recommendations from the ADA for the prevention, screening, diagnosis, management and treatment of diabetic neuropathy, as well as recommended research and clinical trial neuropathy end points

Glucagon-like peptide-1 receptor agonists may offer a new lifeline for patients with hidradenitis suppurativa, according to researchers

your job is to inform them immediately that you take a GLP-1 agonist and when you last injected